EC Number   |
Inhibitors |
Structure |
|---|
    2.3.1.179 | (2E)-3-(3-chlorophenyl)-N-[4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]prop-2-enamide |
ME0619 |
   |
| 2.3.1.179 | 1,3-dichloro-7-(2,4-dihydroxy-6-methylphenyl)-2,4,6,9-tetrahydroxy-12,12-dimethyltetracen-5(12H)-one |
i.e. fasamycin B |
|
| 2.3.1.179 | 1-chloro-7-(2,4-dihydroxy-6-methylphenyl)-2,4,6,9-tetrahydroxy-12,12-dimethyltetracen-5(12H)-one |
i.e. fasamycin A |
|
| 2.3.1.179 | 2-[(2R)-4-ethyl-3-hydroxy-2-[(1E)-2-methylbuta-1,3-dien-1-yl]-5-oxo-2,5-dihydrothiophen-2-yl]acetamide |
- |
|
| 2.3.1.179 | 3,6-dichloro-N-[4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-1-benzothiophene-2-carboxamide |
ME0640 |
|
| 2.3.1.179 | 3,6-dichloro-N-[5-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]pyridin-2-yl]-1-benzothiophene-2-carboxamide |
ME0518 |
|
| 2.3.1.179 | 3-(benzoylamino)-2-hydroxybenzoic acid |
binds outside the active site of the enzyme, binding structure with wild-type and C164Q mutant enzymes, overview. Access to the depths of the active site of the PaFabF apoenzyme is restricted by the conformations of Phe230 and Phe400. 3-(benzoylamino)-2-hydroxybenzoic acid/Mg2+ ion pair selectively binds into and perhaps contributes to the formation of a stable binding site on the surface of the enzyme distant from the active site, from which it is likely to be occluded by steric hindrance |
|
| 2.3.1.179 | 3-benzamido-2-hydroxybenzoic acid |
- |
|
| 2.3.1.179 | 5-chloro-2-(2,4-dichlorophenoxy)phenol |
Triclosan |
|
| 2.3.1.179 | Acyl carrier protein |
0.0017 mM, 50% inhibition of myristic acid transfer from myristoyl-[acyl-carrier protein] to wild-type enzyme |
|
